|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To reconstruct the microRNAs-genes regulatory network in breast cancer, we employed the expression data from The Cancer Genome Atlas (TCGA) related to five essential miRNAs including miR-21, miR-22, miR-210, miR-221, and miR-222, and their associated functional genomics data from the GEO database.
|
30859354 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-222 reprogrammed cancer-associated fibroblasts enhance growth and metastasis of breast cancer.
|
31481734 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim pathway.
|
31273056 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, detection of the miRNA-17-5p, miR-155 and miRNA-222 expression levels in serum samples is significant promising molecular markers for early breast cancer diagnosis.
|
29925280 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study suggests the possible involvement of miR-222-3p expression in breast cancer cell apoptosis, triggered by vincristine, vinblastine, and vinorelbine.
|
30417784 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Exosome-mediated miR-222 transferring: An insight into NF-κB-mediated breast cancer metastasis.
|
29778754 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer.
|
29969658 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, upon analyzing the collected published information, we noticed that the overexpression of miR-155, miR-222, miR-125b, and miR-21 predicts the resistance to the most common systemic treatments; nonetheless, the function of these particular miRNAs must be carefully studied and further analyses are still necessary to increase knowledge about their role and future potential clinical uses in BC.
|
28574440 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-222 Expression as a Predictive Marker for Tumor Progression in Hormone Receptor-Positive Breast Cancer.
|
28382093 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In our previous study, through miRNA microarray and experiments, we have emphasized that miR-222 could promote the ADR-resistance in breast cancer cells.
|
27746366 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since miR-222 might contribute to chemoresistance in many cancer types, in this study, we aimed to investigate its efficacy in breast cancer through PTEN/Akt/p27 <sup>kip1</sup> pathway.
|
27699665 |
2016 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Pure invasive BCs showed a positive correlation of miR-221 and miR-222 with TIMP3 mRNA levels (P = 0.008, r = 0.508, and P = 0.010, r = 0.497, respectively).
|
27488105 |
2016 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Individual miR-222 molecules in BCa cells were detected by fluorescence in situ hybridization (FISH).
|
26432333 |
2016 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Functions of miR-146a and miR-222 in Tumor-associated Macrophages in Breast Cancer.
|
26689540 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
|
23994196 |
2013 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Among the miRNAs involved in breast cancer, miR-221 plays a crucial role for the following reasons: i) miR-221 is significantly overexpressed in triple-negative primary breast cancer; ii) the oncosuppressor p27Kip1, a validated miR-221 target is downregulated in aggressive cancer cell lines; and iii) the upregulation of a key transcription factor, Slug, appears to be crucial, since it binds to the miR-221/miR-222 promoter and is responsible for the high expression of the miR-221/miR-222 cluster in breast cancer cells.
|
23939688 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we find that nucleolin (NCL), a major nucleolar protein, posttranscriptionally regulates the expression of a specific subset of miRNAs, including miR-21, miR-221, miR-222, and miR-103, that are causally involved in breast cancer initiation, progression, and drug resistance.
|
23610125 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of genome-wide miRNA analysis using SOLiD sequencing, 7 miRNAs were found to be co-upregulated (i.e., miR-103, miR-23a, miR-29a, miR-222, miR-23b, miR-24 and miR-25). miR-222 was significantly increased in the serum of BC patients by further validation(P<0.05), which may be a useful biomarker for differentiating BC patients from controls with receiver operating characteristic (ROC) curve area 0.67 of (95% CI=0.5649 to 0.7775).
|
22387599 |
2012 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of miR-222 and miR-296 did not exhibit any significant difference between the breast cancer and normal tissue.
|
21270527 |
2011 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
|
20099276 |
2010 |